RxDoctor Payments Data

Christian McElhinney, MD

Gastroenterology · Overland Park, KSNPI 1508836008

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 428 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 28.5% of the total. 2025 is the largest year on record at $2,149, 5.2 times the $413 reported in 2019.

$6,616in general payments, 2019–2025

Across 428 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$845
  • Bristol Myers Squibb$579
  • Johnson & Johnson$463
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$382
  • Pfizer$360
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,586100%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,616 in reported general payments places this provider in the 80th percentile of 98 gastroenterology providers in Kansas.

See all gastroenterology providers in Kansas

Medicare billing

Part B allowed, 2024
$298,541
Medicare patients
538
Services billed
9,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide40$26,736
Mesalamine48$23,821
CreonLipase/Protease/Amylase35$17,977
Mesalamine ErMesalamine50$12,105
ErythromycinErythromycin Base20$9,507
CholestyramineCholestyramine (With Sugar)73$4,595
Budesonide DrBudesonide23$4,226
Pantoprazole Sodium274$3,643
Balsalazide Disodium18$3,514
Omeprazole331$3,512
Budesonide EcBudesonide13$2,785
Sucralfate59$2,419
Azathioprine24$1,269
Ursodiol16$1,259
Colestipol Hcl18$1,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,887$44,71375 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 98 gastroenterology providers in Kansas.

Other gastroenterology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →